---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Indication"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Indication. Topics: Proposed indication: hypoglycemia due to tumor HI, as named in the FDA designations; Population of the registrational study: insulinoma and non-islet cell tumors; European Union orphan designation: intended use in insulinoma; Approval status. 4 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/indication"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Indication

<a id="heading-2.1.2.5"></a>

## 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

### Proposed indication: hypoglycemia due to tumor HI, as named in the FDA designations

> “Orphan Designation: treatment of hypoglycemia due to tumor-associated hyperinsulinism”

Source: [FDA Orphan Drug Designations and Approvals (2024)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=966723)

> “today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ersodetug for the treatment of hypoglycemia due to tumor HI.”

Source: [Rezolute tumor HI orphan drug designation release (2024)](https://ir.rezolutebio.com/news/detail/343/fda-grants-orphan-drug-designation-to-rezolutes-ersodetug-rz358-for-the-treatment-of-hypoglycemia-due-to-tumor-hyperinsulinism)

> “today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its investigational therapy, ersodetug, for the treatment of hypoglycemia caused by tumor HI.”

Source: [Rezolute tumor HI breakthrough therapy release (2025)](https://ir.rezolutebio.com/news/detail/354/rezolute-receives-breakthrough-therapy-designation-from-fda-for-ersodetug-in-the-treatment-of-hypoglycemia-due-to-tumor-hyperinsulinism)

<a id="topic-2.1.2.5-2"></a>

### Population of the registrational study: insulinoma and non-islet cell tumors

> “The upLIFT Phase 3 registrational study is a single-arm, open-label, pivotal trial in approximately 16 participants with insulinoma or non-islet cell tumors who have uncontrolled hypoglycemia caused by tumor hyperinsulinism (HI).”
> “The 16 enrolled participants include four with non-islet cell tumors and 12 with insulin-secreting malignant islet cell tumors (insulinomas).”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="topic-2.1.2.5-3"></a>

### European Union orphan designation: intended use in insulinoma

> “This medicine was designated as an orphan medicine for the treatment of insulinoma on 12 January 2024.”

Source: [EMA insulinoma orphan designation (2024)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2879)

<a id="topic-2.1.2.5-4"></a>

### Approval status

> “Ersodetug for the treatment of HI is investigational. Statements about safety and efficacy have not been approved by any health authority.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
